May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...

Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” getty Stock image of baby powder Johnson & Johnson has offered ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” getty Stock image of baby powder Johnson & Johnson has offered to pay ...

J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments. J&J will pay $52.50 for each ...

Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...

Pharmaceutical giant Johnson & Johnson is set to pay $6.475 billion to settle lawsuits alleging its talc-based products, often associated with health concerns, caused cancer. This unprecedented ...

(Reuters) -Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis ...

Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged ...

NEW BRUNSWICK, N.J., May 31, 2024--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.